Head-To-Head Review: Butterfly Network (NYSE:BFLY) vs. Precipio (NASDAQ:PRPO)

Butterfly Network (NYSE:BFLY) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Butterfly Network and Precipio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Precipio	-3.57%	-6.73%	-4.49%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Butterfly Network and Precipio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1	2	3	0	2.33
Precipio	1	0	0	0	1.00

Butterfly Network currently has a consensus price target of $5.56, indicating a potential upside of 23.75%. Given Butterfly Network’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Butterfly Network is more favorable than Precipio.

Valuation & Earnings

This table compares Butterfly Network and Precipio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61 million	11.73	-$77.06 million	($0.30)	-14.98
Precipio	$24.05 million	1.70	-$360,000.00	($0.47)	-48.51

Precipio has lower revenue, but higher earnings than Butterfly Network. Precipio is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 25.2% of Butterfly Network shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Butterfly Network has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Summary

Butterfly Network beats Precipio on 10 of the 14 factors compared between the two stocks.

About Butterfly Network

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

About Precipio

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.